{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:47:26Z","timestamp":1790970446079,"version":"4.1.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00702-012-0893-9","type":"journal-article","created":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T05:57:47Z","timestamp":1348466267000},"page":"275-290","source":"Crossref","is-referenced-by-count":157,"title":["Immunogenicity of botulinum toxins"],"prefix":"10.1007","volume":"120","author":[{"given":"Markus","family":"Naumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee Ming","family":"Boo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor J.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,25]]},"reference":[{"key":"893_CR1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/014107689208500906","volume":"85","author":"TJ Anderson","year":"1992","unstructured":"Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, Marsden CD (1992) Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 85:524\u2013529","journal-title":"J R Soc Med"},{"issue":"Suppl 5","key":"893_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1468-1331.2001.00035.x","volume":"8","author":"KR Aoki","year":"2001","unstructured":"Aoki KR, Guyer B (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8(Suppl 5):21\u201329","journal-title":"Eur J Neurol"},{"issue":"Suppl 8","key":"893_CR3","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/mds.20020","volume":"19","author":"MZ Atassi","year":"2004","unstructured":"Atassi MZ (2004) Basic immunological aspects of botulinum toxin therapy. Mov Disord 19(Suppl 8):S68\u2013S84","journal-title":"Mov Disord"},{"key":"893_CR4","doi-asserted-by":"crossref","unstructured":"Atassi MZ (2006) On the enhancement of anti-neurotoxin antibody production by subcomponents HA1 and HA3b of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 152(Pt 7):1891\u20131895; discussion 1895\u20131897","DOI":"10.1099\/mic.0.28862-0"},{"key":"893_CR5","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1016\/j.molimm.2008.06.031","volume":"45","author":"MZ Atassi","year":"2008","unstructured":"Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR (2008) Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol 45:3878\u20133888. doi: 10.1016\/j.molimm.2008.06.031","journal-title":"Mol Immunol"},{"key":"893_CR6","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.imbio.2010.12.009","volume":"216","author":"MZ Atassi","year":"2011","unstructured":"Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR (2011) Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 216:782\u2013792. doi: 10.1016\/j.imbio.2010.12.009","journal-title":"Immunobiology"},{"key":"893_CR7","unstructured":"AVONEX\u00ae [package insert] (2006). Biogen Idec, Inc., Cambridge, MA"},{"key":"893_CR8","first-page":"520","volume":"10","author":"S Badarny","year":"2008","unstructured":"Badarny S, Susel Z, Honigman S (2008) Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox. Isr Med Assoc J 10:520\u2013522","journal-title":"Isr Med Assoc J"},{"key":"893_CR9","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/jnnp.2003.035139","volume":"75","author":"AM Bakheit","year":"2004","unstructured":"Bakheit AM, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L (2004) The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 75:1558\u20131561","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 2","key":"893_CR10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1468-1331.2009.02878.x","volume":"16","author":"R Benecke","year":"2009","unstructured":"Benecke R (2009) Xeomin in the treatment of cervical dystonia. Eur J Neurol 16(Suppl 2):6\u201310","journal-title":"Eur J Neurol"},{"key":"893_CR11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/exnr.2000.7583","volume":"168","author":"H Bigalke","year":"2001","unstructured":"Bigalke H, Wohlfarth K, Irmer A, Dengler R (2001) Botulinum A toxin: dysport improvement of biological availability. Exp Neurol 168:162\u2013170","journal-title":"Exp Neurol"},{"issue":"Suppl 2","key":"893_CR12","first-page":"A87","volume":"74","author":"W Birmingham","year":"2010","unstructured":"Birmingham W, Chinnapongse R, Lew M, Pagan F, Reinhard S, Ferreira J (2010) Immunogenicity analysis from a randomized, double-blind study to compare the efficacy and safety of NeuroBloc (Myobloc\/rimabotulinumtoxinB; BoNT-B) with onabotulinumA (Botox; BoNT-A) in patients with cervical dystonia (CD) who have never previously received a botulinum toxin product (402CD-EU). Neurology 74(Suppl 2):A87\u2013A88","journal-title":"Neurology"},{"key":"893_CR13","first-page":"238","volume":"9","author":"J Bl\u00fcmel","year":"2006","unstructured":"Bl\u00fcmel J, Frevert J, Medawar P (2006) Comparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbit. Neurotox Res 9:238","journal-title":"Neurotox Res"},{"key":"893_CR14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0091270004269646","volume":"45","author":"D Bosse","year":"2005","unstructured":"Bosse D, Praus M, Kiessling P, Nyman L, Andresen C, Waters J, Schindel F (2005) Phase I comparability of recombinant human albumin and human serum albumin. J Clin Pharmacol 45:57\u201367","journal-title":"J Clin Pharmacol"},{"key":"893_CR15","unstructured":"BOTOX\u00ae [package insert] (2011) Allergan, Inc., Irvine, CA"},{"key":"893_CR16","unstructured":"BOTOX\u00ae Cosmetic [package insert] (2011) Allergan, Inc., Irvine, CA"},{"key":"893_CR17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1021\/mp0601244","volume":"4","author":"DT Brandau","year":"2007","unstructured":"Brandau DT, Joshi SB, Smalter AM, Kim S, Steadman B, Middaugh CR (2007) Stability of the Clostridium botulinum type A neurotoxin complex: an empirical phase diagram based approach. Mol Pharm 4:571\u2013582","journal-title":"Mol Pharm"},{"key":"893_CR18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF00867425","volume":"242","author":"JW Brans","year":"1995","unstructured":"Brans JW, de Boer IP, Aramideh M, Ongerboer de Visser BW, Speelman JD (1995) Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. J Neurol 242:529\u2013534","journal-title":"J Neurol"},{"key":"893_CR19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa011892","volume":"347","author":"A Brashear","year":"2002","unstructured":"Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C (2002) Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 347:395\u2013400","journal-title":"N Engl J Med"},{"key":"893_CR20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.apmr.2003.08.077","volume":"85","author":"A Brashear","year":"2004","unstructured":"Brashear A, McAfee AL, Kuhn ER, Fyffe J (2004) Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 85:705\u2013709","journal-title":"Arch Phys Med Rehabil"},{"key":"893_CR21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/BF02850184","volume":"22","author":"A Brashear","year":"2005","unstructured":"Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J (2005) Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther 22:49\u201355. doi: 10.1007\/BF02850184","journal-title":"Adv Ther"},{"key":"893_CR22","unstructured":"Brin MF, Dressler D, Aoki KR (2004) Pharmacology of botulinum toxin therapy. In: Brin MF, Cornella C, Jankovic J (eds) Dystonia: etiology, clinical features, and treatment. Lippincott, Williams & Wilkins, Philadelphia, PA, pp 93\u2013112"},{"key":"893_CR23","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","volume":"23","author":"MF Brin","year":"2008","unstructured":"Brin MF, Comella CL, Jankovic J, Lai F, Naumann M (2008) Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 23:1353\u20131360","journal-title":"Mov Disord"},{"key":"893_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clindermatol.2003.12.027","volume":"22","author":"JE Callaway","year":"2004","unstructured":"Callaway JE (2004) Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol 22:23\u201328","journal-title":"Clin Dermatol"},{"key":"893_CR25","first-page":"1","volume":"7","author":"A Carruthers","year":"2004","unstructured":"Carruthers A, Carruthers J, Lowe N, Menter A, Gibson J, Nordquist M, Mordaunt J, for the BOTOX Glabellar Lines I & II Study Groups (2004) One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res 7:1\u201320","journal-title":"J Clin Res"},{"key":"893_CR26","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1128\/IAI.65.5.1626-1630.1997","volume":"65","author":"F Chen","year":"1997","unstructured":"Chen F, Kuziemko GM, Amersdorfer P, Wong C, Marks JD, Stevens RC (1997) Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms. Infect Immun 65:1626\u20131630","journal-title":"Infect Immun"},{"issue":"Suppl 2","key":"893_CR27","first-page":"A86","volume":"74","author":"R Chinnapongse","year":"2010","unstructured":"Chinnapongse R, Lew M, Pagan F, Reinhard S, Birmingham W (2010) A 7-year open-label safety and immunogenicity study of Myobloc (rimabotulinumtoxinB; BoNT-B) in patients with cervical dystonia-(401CD-NA). Neurology 74(Suppl 2):A86","journal-title":"Neurology"},{"issue":"Suppl 2","key":"893_CR28","first-page":"A88","volume":"74","author":"C Coleman","year":"2010","unstructured":"Coleman C, Hubble J, Schwab J, Beffy J-L, Picaut P, Morte C (2010) Seroconversion in cervical dystonia patients after treatment with abobotulinumtoxin A. Neurology 74(Suppl 2):A88\u2013A89","journal-title":"Neurology"},{"key":"893_CR29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","volume":"60","author":"F Cruz","year":"2011","unstructured":"Cruz F, Herschorn S, Aliotta P, Brin MF, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C (2011) Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 60:742\u2013750","journal-title":"Eur Urol"},{"key":"893_CR30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0041-0101(84)90085-0","volume":"22","author":"BR Das Gupta","year":"1984","unstructured":"Das Gupta BR, Suathyamoorthy V (1984) Purification and amino acid composition of type A botulinum neurotoxin. Toxicon 22:415\u2013424","journal-title":"Toxicon"},{"key":"893_CR31","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/IAI.14.3.680-686.1976","volume":"14","author":"BR Das Gupta","year":"1976","unstructured":"Das Gupta BR, Sugiyama V (1976) Molecular forms of neurotoxins in proteolytic Clostridium botulinum type B cultures. Infect Immun 14:680\u2013686","journal-title":"Infect Immun"},{"key":"893_CR32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1081\/IMM-120016244","volume":"31","author":"BZ Dolimbek","year":"2002","unstructured":"Dolimbek BZ, Jankovic J, Atassi MZ (2002) Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest 31:247\u2013262","journal-title":"Immunol Invest"},{"key":"893_CR33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.molimm.2006.03.011","volume":"44","author":"BZ Dolimbek","year":"2007","unstructured":"Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ (2007) Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT\/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT\/A. Mol Immunol 44:1029\u20131041","journal-title":"Mol Immunol"},{"key":"893_CR34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1007\/s00415-005-0774-3","volume":"252","author":"D Dressler","year":"2005","unstructured":"Dressler D, Bigalke H (2005) Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure. J Neurol 252:904\u2013907","journal-title":"J Neurol"},{"issue":"Suppl 2","key":"893_CR35","first-page":"51","volume":"15","author":"D Dressler","year":"2000","unstructured":"Dressler D, Dimberger G (2000) Botulinum toxin therapy: risk factors for therapy failure [abstract]. Mov Disord 15(Suppl 2):51","journal-title":"Mov Disord"},{"key":"893_CR36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF03033929","volume":"9","author":"D Dressler","year":"2006","unstructured":"Dressler D, Eleopra R (2006) Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res 9:121\u2013125","journal-title":"Neurotox Res"},{"issue":"Suppl 1","key":"893_CR37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","volume":"13","author":"D Dressler","year":"2006","unstructured":"Dressler D, Hallett M (2006) Immunological aspects of Botox, Dysport and Myobloc\/NeuroBloc. Eur J Neurol 13(Suppl 1):11\u201315","journal-title":"Eur J Neurol"},{"key":"893_CR38","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1007\/s004150070132","volume":"247","author":"D Dressler","year":"2000","unstructured":"Dressler D, Bigalke H, Rothwell JC (2000) The sternocleidomastoid test: an in vivo assay to investigate botulinum toxin antibody formation in humans. J Neurol 247:630\u2013632","journal-title":"J Neurol"},{"key":"893_CR39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000047963","volume":"47","author":"D Dressler","year":"2002","unstructured":"Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H (2002) Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 47:118\u2013121","journal-title":"Eur Neurol"},{"key":"893_CR40","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00415-003-1129-6","volume":"250","author":"D Dressler","year":"2003","unstructured":"Dressler D, Bigalke H, Benecke R (2003) Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure. J Neurol 250:967\u2013969","journal-title":"J Neurol"},{"key":"893_CR41","unstructured":"DYSPORT\u2122 [package insert] (2010) Ipsen Biopharm, Ltd., Wrexham, UK"},{"key":"893_CR42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/00365590601068835","volume":"41","author":"I Ehren","year":"2007","unstructured":"Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, Lafolie P (2007) Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 41:335\u2013340","journal-title":"Scand J Urol Nephrol"},{"key":"893_CR43","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.apmr.2008.01.007","volume":"89","author":"EP Elovic","year":"2008","unstructured":"Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C (2008) Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 89:799\u2013806. doi: 10.1016\/j.apmr.2008.01.007","journal-title":"Arch Phys Med Rehabil"},{"key":"893_CR44","unstructured":"Extavia\u00ae [package insert] (2009) Novartis Pharmaceuticals Corporation, East Hanover, NJ"},{"key":"893_CR45","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/mds.20531","volume":"20","author":"SA Factor","year":"2005","unstructured":"Factor SA, Molho ES, Evans S, Feustel PJ (2005) Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 20:1152\u20131160. doi: 10.1002\/mds.20531","journal-title":"Mov Disord"},{"key":"893_CR46","unstructured":"FDA Approval Package for Xeomin\u00ae (2010) (incobotulinumtoxinA) Injection. vol Application Number 125360. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/125360s0000TOC.cfm"},{"key":"893_CR47","unstructured":"Fink K, Eisele KH, Mander GJ, Taylor HV (2009) The mouse hemidiaphragm assay detects neutralizing anti-botulinum neurotoxin type A antibodies with higher sensitivity than the mouse protection assay. Paper presented at the World Congress of the International Society of Physical and Rehabilitation Medicine, Istanbul, Turkey, June 13\u201317"},{"key":"893_CR48","first-page":"325","volume":"4","author":"J Frevert","year":"2010","unstructured":"Frevert J, Dressler D (2010) Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 4:325\u2013332","journal-title":"Biologics"},{"issue":"Suppl 1","key":"893_CR49","first-page":"S60","volume":"24","author":"A Garcia","year":"2009","unstructured":"Garcia A, Trottenberg T, Lobsien E, Andreas K (2009) Comparison of extensor-digitorum-brevis (EDB) test vs mouse diaphragm assay (MDA) as indirect test methods for detection of botulinum toxin A (BTXA) antibodies in clinical practice. Mov Disord 24(Suppl 1):S60","journal-title":"Mov Disord"},{"key":"893_CR50","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1212\/01.WNL.0000144349.95487.91","volume":"63","author":"MF Gordon","year":"2004","unstructured":"Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, Turkel C (2004) Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 63:1971\u20131973. doi: 10.1212\/01.WNL.0000144349.95487.91","journal-title":"Neurology"},{"key":"893_CR51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H G\u00f6schel","year":"1997","unstructured":"G\u00f6schel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2014therapeutic consequences. Exp Neurol 147:96\u2013102. doi: 10.1006\/exnr.1997.6580","journal-title":"Exp Neurol"},{"key":"893_CR52","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.2146\/ajhp080210","volume":"65","author":"S Gottlieb","year":"2008","unstructured":"Gottlieb S (2008) Biosimilars: policy, clinical, and regulatory considerations. Am J Health Syst Pharm 65:S2\u2013S8. doi: 10.2146\/ajhp080210","journal-title":"Am J Health Syst Pharm"},{"key":"893_CR53","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"P Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9:213\u2013217. doi: 10.1002\/mds.870090216","journal-title":"Mov Disord"},{"key":"893_CR54","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.eururo.2010.06.035","volume":"58","author":"P Grise","year":"2010","unstructured":"Grise P, Ruffion A, Denys P, Egon G, Chartier Kastler E (2010) Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. Eur Urol 58:759\u2013766","journal-title":"Eur Urol"},{"key":"893_CR55","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1464-410X.2009.08466.x","volume":"104","author":"J Grosse","year":"2009","unstructured":"Grosse J, Kramer G, Jakse G (2009) Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study. BJU Int 104:651\u2013656","journal-title":"BJU Int"},{"key":"893_CR56","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1126\/science.1214270","volume":"335","author":"S Gu","year":"2012","unstructured":"Gu S, Rumpel S, Zhou J, Strotmeier J, Bigalke H, Perry K, Shoemaker CB, Rummel A, Jin R (2012) Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science 335:977\u2013981","journal-title":"Science"},{"key":"893_CR57","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1128\/IAI.57.1.18-22.1989","volume":"57","author":"JL Halpern","year":"1989","unstructured":"Halpern JL, Smith LA, Seamon KB, Groover KA, Habig WH (1989) Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody. Infect Immun 57:18\u201322","journal-title":"Infect Immun"},{"key":"893_CR58","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","volume":"50","author":"PA Hanna","year":"1998","unstructured":"Hanna PA, Jankovic J (1998) Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology 50:1624\u20131629","journal-title":"Neurology"},{"key":"893_CR59","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/jnnp.66.5.612","volume":"66","author":"PA Hanna","year":"1999","unstructured":"Hanna PA, Jankovic J, Vincent A (1999) Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 66:612\u2013616","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"893_CR60","first-page":"93","volume-title":"Therapy with botulinum toxin","author":"CL Hatheway","year":"1994","unstructured":"Hatheway CL, Dang C (1994) Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 93\u2013107"},{"key":"893_CR61","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","volume":"19","author":"P Haussermann","year":"2004","unstructured":"Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19:303\u2013308. doi: 10.1002\/mds.10659","journal-title":"Mov Disord"},{"key":"893_CR62","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","volume":"17","author":"GY Hsiung","year":"2002","unstructured":"Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288\u20131293. doi: 10.1002\/mds.10252","journal-title":"Mov Disord"},{"key":"893_CR63","unstructured":"HUMIRA\u00ae [package insert] (2011) Abbott Laboratories, North Chicago, IL"},{"key":"893_CR64","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e3181acefaf","volume":"32","author":"T Hunt","year":"2009","unstructured":"Hunt T, Clarke K (2009) Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol 32:28\u201331","journal-title":"Clin Neuropharmacol"},{"key":"893_CR65","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF01569055","volume":"28","author":"RA Hutson","year":"1994","unstructured":"Hutson RA, Collins MD, East AK, Thompson DE (1994) Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum type B neurotoxin: comparison with other clostridial neurotoxins. Curr Microbiol 28:101\u2013110","journal-title":"Curr Microbiol"},{"key":"893_CR66","first-page":"28","volume":"4","author":"M Imhof","year":"2011","unstructured":"Imhof M, K\u00fchne U (2011) A phase III study of incobotulinumtoxinA in the treatment of glabellar frown lines. J Clin Aesthet Dermatol 4:28\u201334","journal-title":"J Clin Aesthet Dermatol"},{"key":"893_CR67","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/IAI.64.5.1589-1594.1996","volume":"64","author":"K Inoue","year":"1996","unstructured":"Inoue K, Fujinaga Y, Watanabe T, Ohyama T, Takeshi K, Moriishi K, Nakajima H, Oguma K (1996) Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64:1589\u20131594","journal-title":"Infect Immun"},{"key":"893_CR68","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archneur.1991.00530240057020","volume":"48","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Schwartz KS (1991) Clinical correlates of response to botulinum toxin injections. Arch Neurol 48:1253\u20131256","journal-title":"Arch Neurol"},{"key":"893_CR69","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","volume":"45","author":"J Jankovic","year":"1995","unstructured":"Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45:1743\u20131746","journal-title":"Neurology"},{"key":"893_CR70","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60:1186\u20131188","journal-title":"Neurology"},{"key":"893_CR71","doi-asserted-by":"crossref","unstructured":"Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ (2006) Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67:2233\u20132235. doi: 10.1212\/01.wnl.0000249308.66959.43","DOI":"10.1212\/01.wnl.0000249308.66959.43"},{"key":"893_CR72","doi-asserted-by":"crossref","unstructured":"Joshi SG, Elias M, Singh A, Al-Saleem FH, Ancharski D, Nasser Z, Takahashi T, Simpson LL (2011) Modulation of botulinum toxin-induced changes in neuromuscular function with antibodies directed against recombinant polypeptides or fragments. Neuroscience 179:208\u2013222","DOI":"10.1016\/j.neuroscience.2011.01.033"},{"key":"893_CR73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/WNF.0b013e3181b13308","volume":"32","author":"P Kanovsky","year":"2009","unstructured":"Kanovsky P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, Grafe S (2009) Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 32:259\u2013265. doi: 10.1097\/WNF.0b013e3181b13308","journal-title":"Clin Neuropharmacol"},{"key":"893_CR74","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-4632.2009.04071.x","volume":"48","author":"M Kawashima","year":"2009","unstructured":"Kawashima M, Harii K (2009) An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol 48:768\u2013776. doi: 10.1111\/j.1365-4632.2009.04071.x","journal-title":"Int J Dermatol"},{"key":"893_CR75","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.870120116","volume":"12","author":"KR Kessler","year":"1997","unstructured":"Kessler KR, Benecke R (1997) The EBD test\u2014a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12:95\u201399. doi: 10.1002\/mds.870120116","journal-title":"Mov Disord"},{"key":"893_CR76","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","volume":"246","author":"KR Kessler","year":"1999","unstructured":"Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246:265\u2013274","journal-title":"J Neurol"},{"key":"893_CR77","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1504\/TBJ.2008.018954","volume":"1","author":"KM Krebs","year":"2008","unstructured":"Krebs KM, Lebeda FJ (2008) Comparison of the structural features of botulinum neurotoxin and NTNH, a non-toxic accessory protein of the progenitor complex. Botulinum J 1:116\u2013134","journal-title":"Botulinum J"},{"key":"893_CR78","doi-asserted-by":"crossref","first-page":"14316","DOI":"10.1021\/bi701564f","volume":"46","author":"RV Kukreja","year":"2007","unstructured":"Kukreja RV, Singh BR (2007) Comparative role of neurotoxin-associated proteins in the structural stability and endopeptidase activity of botulinum neurotoxin complex types A and E. Biochemistry 46:14316\u201314324","journal-title":"Biochemistry"},{"key":"893_CR79","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.toxicon.2009.01.017","volume":"53","author":"R Kukreja","year":"2009","unstructured":"Kukreja R, Chang TW, Cai S, Lindo P, Riding S, Zhou Y, Ravichandran E, Singh BR (2009) Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon 53:616\u2013624","journal-title":"Toxicon"},{"key":"893_CR80","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WNF.0b013e3181914d0a","volume":"32","author":"O Lange","year":"2009","unstructured":"Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K (2009) Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 32:213\u2013218. doi: 10.1097\/WNF.0b013e3181914d0a","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl 6","key":"893_CR81","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.asj.2009.09.009","volume":"29","author":"I Lawrence","year":"2009","unstructured":"Lawrence I, Moy R (2009) An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A. Aesthet Surg J 29(Suppl 6):S66\u2013S71","journal-title":"Aesthet Surg J"},{"issue":"Pt 11","key":"893_CR82","first-page":"3739","volume":"151","author":"JC Lee","year":"2005","unstructured":"Lee JC, Yokota K, Arimitsu H, Hwang HJ, Sakaguchi Y, Cui J, Takeshi K, Watanabe T, Ohyama T, Oguma K (2005) Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin. Microbiology 151(Pt 11):3739\u20133747. doi: 10.1099\/mic.0.28421-0","journal-title":"Microbiology"},{"issue":"Suppl 2","key":"893_CR83","first-page":"A86","volume":"74","author":"M Lew","year":"2010","unstructured":"Lew M, Chinnapongse R, Pagan F, Reinhard S, Birmingham W (2010) An open-label, safety and immunogenicity study of Myobloc (rimabotulinumtoxinB; BoNT-B) in patients with cervical dystonia-(351). Neurology 74(Suppl 2):A86","journal-title":"Neurology"},{"key":"893_CR84","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s10930-008-9151-2","volume":"27","author":"MA Lietzow","year":"2008","unstructured":"Lietzow MA, Gielow ET, Le D, Zhang J, Verhagen MF (2008) Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J 27:420\u2013425","journal-title":"Protein J"},{"key":"893_CR85","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","volume":"20","author":"NI Mejia","year":"2005","unstructured":"Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20:592\u2013597. doi: 10.1002\/mds.20376","journal-title":"Mov Disord"},{"key":"893_CR86","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1590\/S0004-282X2007000400009","volume":"65","author":"C Menezes","year":"2007","unstructured":"Menezes C, Rodrigues B, Magalhaes E, Melo A (2007) Botulinum toxin type A in refractory chronic migraine: an open-label trial. Arq Neuropsiquiatr 65:596\u2013598","journal-title":"Arq Neuropsiquiatr"},{"key":"893_CR87","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.4049\/jimmunol.1002156","volume":"185","author":"SB Mizel","year":"2010","unstructured":"Mizel SB, Bates JT (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185:5677\u20135682. doi: 10.4049\/jimmunol.1002156","journal-title":"J Immunol"},{"key":"893_CR88","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaad.2009.03.049","volume":"61","author":"GD Monheit","year":"2009","unstructured":"Monheit GD, Cohen JL (2009) Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol 61:421\u2013425. doi: 10.1016\/j.jaad.2009.03.049","journal-title":"J Am Acad Dermatol"},{"key":"893_CR89","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/jnnp.54.9.813","volume":"54","author":"AP Moore","year":"1991","unstructured":"Moore AP, Blumhardt LD (1991) A double blind trial of botulinum toxin \u201cA\u201d in torticollis, with one year follow up. J Neurol Neurosurg Psychiatry 54:813\u2013816","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"893_CR90","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archfacial.2009.5","volume":"11","author":"R Moy","year":"2009","unstructured":"Moy R, Maas C, Monheit G, Huber MB (2009) Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 11:77\u201383. doi: 10.1001\/archfacial.2009.5","journal-title":"Arch Facial Plast Surg"},{"key":"893_CR91","first-page":"71","volume-title":"Therapy with botulinum toxin","author":"E Moyer","year":"1994","unstructured":"Moyer E, Setler PE (1994) Botulinum toxin type B: experimental and clinical experience. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, Inc., New York, pp 71\u201395"},{"key":"893_CR92","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00702-009-0223-z","volume":"116","author":"K Muller","year":"2009","unstructured":"Muller K, Mix E, Adib Saberi F, Dressler D, Benecke R (2009) Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm 116:579\u2013585. doi: 10.1007\/s00702-009-0223-z","journal-title":"J Neural Transm"},{"key":"893_CR93","unstructured":"MYOBLOC\u00ae [package insert] (2010) Solstice Neuroscience, Inc., San Francisco, CA"},{"issue":"Suppl 1","key":"893_CR94","first-page":"S225","volume":"24","author":"M Naumann","year":"2009","unstructured":"Naumann M, Abu-Shakra S, Boodhoo T, Miller-Messana MA, Demos G, Brin MF (2009) A meta-analysis of neutralizing antibody conversion following a specific formulation of botulinum toxin type A (BoNTA, Allergan, Inc.): an analysis of large clinical trials across five indications [abstract We-156]. Mov Disord 24(Suppl 1):S225","journal-title":"Mov Disord"},{"key":"893_CR95","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","volume":"25","author":"M Naumann","year":"2010","unstructured":"Naumann M, Carruthers A, Carruthers J, Aurora SK, Zafonte R, Abu-Shakra S, Boodhoo T, Miller-Messana MA, Demos G, James L, Beddingfield F, VanDenburgh A, Chapman MA, Brin MF (2010) Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX\u00ae) across multiple indications. Mov Disord 25:2211\u20132218","journal-title":"Mov Disord"},{"key":"893_CR96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1504\/TBJ.2008.018956","volume":"1","author":"N Panjwani","year":"2008","unstructured":"Panjwani N, O\u2019Keeffe R, Pickett A (2008) Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J 1:153\u2013166","journal-title":"Botulinum J"},{"key":"893_CR97","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/j.1468-1331.2007.01683.x","volume":"14","author":"A Pickett","year":"2007","unstructured":"Pickett A, O\u2019Keeffe R, Panjwani N (2007) The protein load of therapeutic botulinum toxins. Eur J Neurol 14:e11","journal-title":"Eur J Neurol"},{"key":"893_CR98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1504\/TBJ.2008.018951","volume":"1","author":"B Poulain","year":"2008","unstructured":"Poulain B, Popoff MR, Molgo J (2008) How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. Botulinum J 1:14\u201387","journal-title":"Botulinum J"},{"key":"893_CR99","unstructured":"Rebif\u00ae [package insert] (2005) Serono, Inc., Rockland, MA"},{"issue":"Suppl 2","key":"893_CR100","first-page":"A86","volume":"74","author":"S Reinhard","year":"2010","unstructured":"Reinhard S, Pagan F, Birmingham W, Lew M, Chinnapongse R, Ferreira J (2010) An open-label safety and immunogenicity study of NeuroBloc (Myobloc; rimabotulinumtoxinB; BoNT-B) in patients with cervical dystonia (CD) (401CD-EU). Neurology 74(Suppl 2):A86","journal-title":"Neurology"},{"key":"893_CR101","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(77)91953-5","volume":"1","author":"J Ring","year":"1977","unstructured":"Ring J, Messmer K (1977) Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1:466\u2013469","journal-title":"Lancet"},{"key":"893_CR102","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","volume":"113","author":"P Roggenkamper","year":"2006","unstructured":"Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S (2006) Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 113:303\u2013312","journal-title":"J Neural Transm"},{"key":"893_CR103","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/MMBR.56.1.80-99.1992","volume":"56","author":"EJ Schantz","year":"1992","unstructured":"Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56:80\u201399","journal-title":"Microbiol Rev"},{"issue":"Suppl 5","key":"893_CR104","first-page":"S22","volume":"55","author":"P Setler","year":"2000","unstructured":"Setler P (2000) The biochemistry of botulinum toxin type B. Neurology 55(Suppl 5):S22\u2013S28","journal-title":"Neurology"},{"issue":"Suppl 6","key":"893_CR105","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1097\/00002508-200211001-00002","volume":"18","author":"PE Setler","year":"2002","unstructured":"Setler PE (2002) Therapeutic use of botulinum toxins: background and history. Clin J Pain 18(Suppl 6):S119\u2013S124","journal-title":"Clin J Pain"},{"key":"893_CR106","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0161-6420(93)31384-9","volume":"100","author":"RM Siatkowski","year":"1993","unstructured":"Siatkowski RM, Tyutyunikov A, Biglan AW, Scalise D, Genovese C, Raikow RB, Kennerdell JS, Feuer WJ (1993) Serum antibody production to botulinum A toxin. Ophthalmology 100:1861\u20131866","journal-title":"Ophthalmology"},{"key":"893_CR107","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","volume":"27","author":"LA Smith","year":"2007","unstructured":"Smith LA, Rusnak JM (2007) Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 27:303\u2013318","journal-title":"Crit Rev Immunol"},{"key":"893_CR108","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","volume":"16","author":"D Truong","year":"2010","unstructured":"Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S (2010) Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16:316\u2013323. doi: 10.1016\/j.parkreldis.2010.03.002","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 2","key":"893_CR109","first-page":"R47","volume":"365","author":"C Turkel","year":"2002","unstructured":"Turkel C, Dru R, Liu J, for the BOTOX Spasticity Study Group (2002) Double-blind, randomized, dose-ranging study of BOTOX\u00ae (botulinum toxin type A) purified neurotoxin complex for treating focal spasticity post-stroke [abstract]. Naunyn Schmiedebergs Arch Pharmacol 365(Suppl 2):R47","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"893_CR110","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AEM.58.8.2345-2354.1992","volume":"58","author":"SM Whelan","year":"1992","unstructured":"Whelan SM, Elmore MJ, Bodsworth NJ, Brehm JK, Atkinson T, Minton NP (1992) Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl Environ Microbiol 58:2345\u20132354","journal-title":"Appl Environ Microbiol"},{"key":"893_CR111","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/PL00004951","volume":"355","author":"K Wohlfarth","year":"1997","unstructured":"Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355:335\u2013340","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"893_CR112","unstructured":"XEOMIN\u00ae [package insert] (2011) Merz Pharmaceuticals, LLC, Greensboro, NC"},{"key":"893_CR113","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.clinthera.2007.04.015","volume":"29","author":"SA Yablon","year":"2007","unstructured":"Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF (2007) Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 29:683\u2013690","journal-title":"Clin Ther"},{"key":"893_CR114","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1126\/science.1215584","volume":"335","author":"SI Yoon","year":"2012","unstructured":"Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, Wilson IA (2012) Structural basis of TLR5-flagellin recognition and signaling. Science 335:859\u2013864. doi: 10.1126\/science.1215584","journal-title":"Science"},{"key":"893_CR115","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1212\/WNL.43.9.1715","volume":"43","author":"M Zuber","year":"1993","unstructured":"Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P (1993) Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology 43:1715\u20131718","journal-title":"Neurology"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-012-0893-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T22:44:47Z","timestamp":1687733087000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-012-0893-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,25]]},"references-count":115,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1007\/s00702-012-0893-9","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,25]]}}}